

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

# Innovent

信達生物製藥

**INNOVENT BIOLOGICS, INC.**

*(Incorporated in the Cayman Islands with Limited Liability)*

**(Stock Code: 1801)**

## **INSIDE INFORMATION ANNOUNCEMENT UPDATE ON THE COMPANY'S PRODUCT REVENUE IN THE FIRST QUARTER OF 2023**

This announcement is made by Innovent Biologics, Inc. (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

In the first quarter of 2023, the Company achieved a total product revenue of approximately RMB1.1 billion, representing a steady quarter-to-quarter growth, mainly driven by continuous volume ramp-up of TYVYT<sup>®</sup> (sintilimab injection) and other products. The impact of the nationwide COVID-19 pandemic on the business of the Company has been gradually diminishing throughout the first quarter, in particular, after the beginning of the quarter. The Company's product sales and promotional activities in domestic markets have returned to normal. Meanwhile, the updated National Reimbursement Drug List has taken effect since March 1, 2023, which includes TYVYT<sup>®</sup> (sintilimab injection) in two new indications (first-line gastric cancer and first-line esophageal cancer), olverematinib for the first listing, BYVASDA<sup>®</sup> (bevacizumab injection), HALPRYZA<sup>®</sup> (rituximab injection) and SULINNO<sup>®</sup> (adalimumab injection) in multiple new indications, further facilitating continuous growth of our product portfolio. Besides, the Company's eighth approved product Retsevmo<sup>®</sup> (selpercatinib) has been officially launched for commercialization in March 2023.

In 2023, the Company anticipates a further expansion of the commercial portfolio and continuous growth of the product revenue. Currently, the Company has eight approved products and three new assets under the New Drug Application (the “**NDA**”) review, which could potentially bring a more diversified commercial portfolio consisting of over ten products within year 2023 and empower the product revenue growth continually.

Meanwhile, the Company will further improve operational productivity and efficiency, based on an enhanced commercial system and preliminary positive results achieved in year 2022, with an aim to achieve long-term sustainable development of the business. Moreover, as several innovative non-oncology candidates with high differentiation and substantial market potential are anticipated to receive approvals or enter late-stage clinical development, the Company plans to build more competitive product portfolios, commercial presence, and brand franchise in non-oncology areas, alongside oncology areas, to support more sustainable and diversified long-term growth of the Company.

The Company currently has eight approved products, including: TYVYT<sup>®</sup> (sintilimab injection), BYVASDA<sup>®</sup> (bevacizumab injection), SULINNO<sup>®</sup> (adalimumab injection), HALPRYZA<sup>®</sup> (rituximab injection), PEMAZYRE<sup>®</sup> (pemigatinib), olverematinib, Cyramza<sup>®</sup> (ramucirumab) and Retsevmo<sup>®</sup> (selpercatinib).

The Company has built a robust pipeline of over 30 valuable assets in the fields of cancer, metabolic, autoimmune diseases and other major therapeutic areas, with 8 products officially approved for marketing in China, 3 assets under the NDA review by the National Medical Products Administration (NMPA), 5 assets in Phase 3 or pivotal clinical trials, and approximately 20 assets in clinical trials. The Company believes that its robust innovative pipeline with great market potential will firmly support the sustainable growth of the Company under the committed strategy of global innovation.

The financial information set out in this announcement was prepared based on internal management records of the Group which have not been audited or reviewed by external auditors, and as such the data is for investors' information only. Such data may differ from figures to be disclosed in the audited or unaudited consolidated financial statements to be published by the Company (including but not limited to those published on an annual or semi-annual basis), due to various uncertainties during the process of collection and collating of such data. This announcement does not constitute, nor should it be construed as, an offer or solicitation for the purchase or sale of any securities or financial instruments of the Group.

By Order of the Board  
**Innovent Biologics, Inc.**  
**Dr. De-Chao Michael Yu**  
*Chairman and Executive Director*

Hong Kong, China, April 27, 2023

*As at the date of this announcement, the Board comprises Dr. De-Chao Michael Yu as Chairman and Executive Director and Mr. Ronald Hao Xi Ede as Executive Director, and Dr. Charles Leland Cooney, Ms. Joyce I-Yin Hsu, Dr. Kaixian Chen and Mr. Gary Zieziula as Independent Non-executive Directors.*